Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Sakura Hosoba, Edmund K. Waller, Neeta Shenvi, Michael Graiser, Kirk A. Easley, Zaid Al-Kadhimi, Akira Andoh, Ana G. Antun, Sheliagh Barclay, Cassandra D. Josephson, Jean L. Koff, H. Jean Khoury, Amelia A. Langston, James C. Zimring, John D. Roback, Cynthia R. Giver

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

More than 90% of allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients receive red blood cell (RBC) or platelet transfusions in the peritransplantation period. We tested the hypothesis that transfusions are associated with the development of severe (grade III-IV) acute graft-versus-host disease (aGVHD) or mortality after allo-HSCT in a retrospective study of 322 consecutive patients receiving an allogeneic bone marrow or granulocyte colony-stimulating factor-mobilized blood stem cell graft for a hematologic malignancy. Counting transfused RBC and platelet units between day −7 pretransplantation and day +27 post-transplantation, but excluding transfusions administered after a diagnosis of aGVHD, yielded medians of 5 RBC units and 2 platelet units transfused. Sixty-three patients (20%) developed a maximal grade III-IV aGVHD with onset up to day +150 post-transplantation (median aGVHD onset of 28 days). HLA mismatch (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.2 to 4.7; P =.01), and transfusion of more than the median number of RBC units (HR, 2.1; 95% CI, 1.1 to 3.7; P =.02) were independently associated with greater risk of grade III-IV aGVHD in a multivariable analysis model. Disease risk strata (HR, 1.7; 95% CI, 1.2 to 2.4 for high risk versus low risk; P =.005) and transfusion of more than the median number of RBC units (HR, 1.4; 95% CI, 1.0 to 2.0; P =.054) were independently associated with inferior overall survival. These data support our hypothesis that peritransplantation RBC transfusions are associated with the risk of developing severe aGVHD and worse overall survival following allo-HSCT, and suggest that strategies to reduce routine RBC transfusion may favorably reduce the incidence and severity of GVHD.

Original languageEnglish (US)
Pages (from-to)973-982
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number5
DOIs
StatePublished - May 2018

Fingerprint

Erythrocyte Transfusion
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Erythrocytes
Confidence Intervals
Blood Platelets
Transplantation
Platelet Transfusion
Survival
Granulocyte Colony-Stimulating Factor
Hematologic Neoplasms
Blood Cells
Stem Cells
Retrospective Studies
Bone Marrow
Transplants
Mortality
Incidence

Keywords

  • Allogeneic BMT
  • Allogeneic HSCT
  • Blood transfusion
  • GVHD
  • Graft-versus-host disease
  • RBC transfusion

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. / Hosoba, Sakura; Waller, Edmund K.; Shenvi, Neeta; Graiser, Michael; Easley, Kirk A.; Al-Kadhimi, Zaid; Andoh, Akira; Antun, Ana G.; Barclay, Sheliagh; Josephson, Cassandra D.; Koff, Jean L.; Khoury, H. Jean; Langston, Amelia A.; Zimring, James C.; Roback, John D.; Giver, Cynthia R.

In: Biology of Blood and Marrow Transplantation, Vol. 24, No. 5, 05.2018, p. 973-982.

Research output: Contribution to journalArticle

Hosoba, S, Waller, EK, Shenvi, N, Graiser, M, Easley, KA, Al-Kadhimi, Z, Andoh, A, Antun, AG, Barclay, S, Josephson, CD, Koff, JL, Khoury, HJ, Langston, AA, Zimring, JC, Roback, JD & Giver, CR 2018, 'Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 24, no. 5, pp. 973-982. https://doi.org/10.1016/j.bbmt.2018.01.003
Hosoba, Sakura ; Waller, Edmund K. ; Shenvi, Neeta ; Graiser, Michael ; Easley, Kirk A. ; Al-Kadhimi, Zaid ; Andoh, Akira ; Antun, Ana G. ; Barclay, Sheliagh ; Josephson, Cassandra D. ; Koff, Jean L. ; Khoury, H. Jean ; Langston, Amelia A. ; Zimring, James C. ; Roback, John D. ; Giver, Cynthia R. / Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2018 ; Vol. 24, No. 5. pp. 973-982.
@article{ca3f372206c244ee8fc2080811e7a513,
title = "Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation",
abstract = "More than 90{\%} of allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients receive red blood cell (RBC) or platelet transfusions in the peritransplantation period. We tested the hypothesis that transfusions are associated with the development of severe (grade III-IV) acute graft-versus-host disease (aGVHD) or mortality after allo-HSCT in a retrospective study of 322 consecutive patients receiving an allogeneic bone marrow or granulocyte colony-stimulating factor-mobilized blood stem cell graft for a hematologic malignancy. Counting transfused RBC and platelet units between day −7 pretransplantation and day +27 post-transplantation, but excluding transfusions administered after a diagnosis of aGVHD, yielded medians of 5 RBC units and 2 platelet units transfused. Sixty-three patients (20{\%}) developed a maximal grade III-IV aGVHD with onset up to day +150 post-transplantation (median aGVHD onset of 28 days). HLA mismatch (hazard ratio [HR], 2.4; 95{\%} confidence interval [CI], 1.2 to 4.7; P =.01), and transfusion of more than the median number of RBC units (HR, 2.1; 95{\%} CI, 1.1 to 3.7; P =.02) were independently associated with greater risk of grade III-IV aGVHD in a multivariable analysis model. Disease risk strata (HR, 1.7; 95{\%} CI, 1.2 to 2.4 for high risk versus low risk; P =.005) and transfusion of more than the median number of RBC units (HR, 1.4; 95{\%} CI, 1.0 to 2.0; P =.054) were independently associated with inferior overall survival. These data support our hypothesis that peritransplantation RBC transfusions are associated with the risk of developing severe aGVHD and worse overall survival following allo-HSCT, and suggest that strategies to reduce routine RBC transfusion may favorably reduce the incidence and severity of GVHD.",
keywords = "Allogeneic BMT, Allogeneic HSCT, Blood transfusion, GVHD, Graft-versus-host disease, RBC transfusion",
author = "Sakura Hosoba and Waller, {Edmund K.} and Neeta Shenvi and Michael Graiser and Easley, {Kirk A.} and Zaid Al-Kadhimi and Akira Andoh and Antun, {Ana G.} and Sheliagh Barclay and Josephson, {Cassandra D.} and Koff, {Jean L.} and Khoury, {H. Jean} and Langston, {Amelia A.} and Zimring, {James C.} and Roback, {John D.} and Giver, {Cynthia R.}",
year = "2018",
month = "5",
doi = "10.1016/j.bbmt.2018.01.003",
language = "English (US)",
volume = "24",
pages = "973--982",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

AU - Hosoba, Sakura

AU - Waller, Edmund K.

AU - Shenvi, Neeta

AU - Graiser, Michael

AU - Easley, Kirk A.

AU - Al-Kadhimi, Zaid

AU - Andoh, Akira

AU - Antun, Ana G.

AU - Barclay, Sheliagh

AU - Josephson, Cassandra D.

AU - Koff, Jean L.

AU - Khoury, H. Jean

AU - Langston, Amelia A.

AU - Zimring, James C.

AU - Roback, John D.

AU - Giver, Cynthia R.

PY - 2018/5

Y1 - 2018/5

N2 - More than 90% of allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients receive red blood cell (RBC) or platelet transfusions in the peritransplantation period. We tested the hypothesis that transfusions are associated with the development of severe (grade III-IV) acute graft-versus-host disease (aGVHD) or mortality after allo-HSCT in a retrospective study of 322 consecutive patients receiving an allogeneic bone marrow or granulocyte colony-stimulating factor-mobilized blood stem cell graft for a hematologic malignancy. Counting transfused RBC and platelet units between day −7 pretransplantation and day +27 post-transplantation, but excluding transfusions administered after a diagnosis of aGVHD, yielded medians of 5 RBC units and 2 platelet units transfused. Sixty-three patients (20%) developed a maximal grade III-IV aGVHD with onset up to day +150 post-transplantation (median aGVHD onset of 28 days). HLA mismatch (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.2 to 4.7; P =.01), and transfusion of more than the median number of RBC units (HR, 2.1; 95% CI, 1.1 to 3.7; P =.02) were independently associated with greater risk of grade III-IV aGVHD in a multivariable analysis model. Disease risk strata (HR, 1.7; 95% CI, 1.2 to 2.4 for high risk versus low risk; P =.005) and transfusion of more than the median number of RBC units (HR, 1.4; 95% CI, 1.0 to 2.0; P =.054) were independently associated with inferior overall survival. These data support our hypothesis that peritransplantation RBC transfusions are associated with the risk of developing severe aGVHD and worse overall survival following allo-HSCT, and suggest that strategies to reduce routine RBC transfusion may favorably reduce the incidence and severity of GVHD.

AB - More than 90% of allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients receive red blood cell (RBC) or platelet transfusions in the peritransplantation period. We tested the hypothesis that transfusions are associated with the development of severe (grade III-IV) acute graft-versus-host disease (aGVHD) or mortality after allo-HSCT in a retrospective study of 322 consecutive patients receiving an allogeneic bone marrow or granulocyte colony-stimulating factor-mobilized blood stem cell graft for a hematologic malignancy. Counting transfused RBC and platelet units between day −7 pretransplantation and day +27 post-transplantation, but excluding transfusions administered after a diagnosis of aGVHD, yielded medians of 5 RBC units and 2 platelet units transfused. Sixty-three patients (20%) developed a maximal grade III-IV aGVHD with onset up to day +150 post-transplantation (median aGVHD onset of 28 days). HLA mismatch (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.2 to 4.7; P =.01), and transfusion of more than the median number of RBC units (HR, 2.1; 95% CI, 1.1 to 3.7; P =.02) were independently associated with greater risk of grade III-IV aGVHD in a multivariable analysis model. Disease risk strata (HR, 1.7; 95% CI, 1.2 to 2.4 for high risk versus low risk; P =.005) and transfusion of more than the median number of RBC units (HR, 1.4; 95% CI, 1.0 to 2.0; P =.054) were independently associated with inferior overall survival. These data support our hypothesis that peritransplantation RBC transfusions are associated with the risk of developing severe aGVHD and worse overall survival following allo-HSCT, and suggest that strategies to reduce routine RBC transfusion may favorably reduce the incidence and severity of GVHD.

KW - Allogeneic BMT

KW - Allogeneic HSCT

KW - Blood transfusion

KW - GVHD

KW - Graft-versus-host disease

KW - RBC transfusion

UR - http://www.scopus.com/inward/record.url?scp=85041613358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041613358&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.01.003

DO - 10.1016/j.bbmt.2018.01.003

M3 - Article

C2 - 29307717

AN - SCOPUS:85041613358

VL - 24

SP - 973

EP - 982

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -